Combining DSIP with other treatments should be approached cautiously to avoid over-sedation, drug interactions, or adverse effects
Within the pancreas, GIP and GLP-1 together promote -cell proliferation and inhibit cell death, thereby resulting in pancreatic -cell mass-increase, while GIP enhances postprandial glucagon response and GLP-1 suppresses it [9, 10]
Several clinical studies have investigated glutathiones skin-brightening abilities because it inhibits an enzyme called tyrosinase, which is responsible for melanin production
As awareness spreads, more physicians are adopting Mounjaro as a frontline treatment option
Studies show berberine activates the G protein-coupled receptor TGR5, which stimulates L-cells to release GLP-1
Quick Answer: No GLP-1 receptor agonist is currently licensed specifically for fatty liver disease in the UK, but semaglutide and liraglutide show the most promising evidence for reducing hepatic steatosis and inflammation in patients with MASLD/NASH